All GLG News Analyses Filed Under: Oncology
Posted February 28, 2008
Roche Herceptin targeted cancer drugs
Analysis of: Cancer drugs should be tailored to fit patient | www.fiercebioresearcher.com
Author: GLG Member Program Contributor
Analysis of: Cancer drugs should be tailored to fit patient | www.fiercebioresearcher.com
Author: GLG Member Program Contributor
Essentially we are moving into an arena where cancer drugs will be more and more specific to individual groups of patients with cancer. For example in breast cancer all patients used to be treated the same. Now patients with tumours that are ER positive are given hormonal therapies and not those with...
Posted February 28, 2008
Novartis's Everolimus: On it's way to being a competitor for Wyeth's Torisel.
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal | online.wsj.com
Author: GLG Member Program Contributor
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal | online.wsj.com
Author: GLG Member Program Contributor
It shares a common mechanism of action with Wyeth's Torisel (mTOR inhibition) and will at least share the market for recurrence after a TK inhibitor fails.
Posted February 26, 2008
Drivers and Passengers: The complexity and heterogeneity of mutational signatures in cancer means that sequencing becomes the easy part.
Analysis of: Study: More Complexity In Tailoring Cancer Drugs | online.wsj.com
Author: GLG Member Program Contributor
Analysis of: Study: More Complexity In Tailoring Cancer Drugs | online.wsj.com
Author: GLG Member Program Contributor
In the accident of the cancer genome there will always be collateral
damage. The difficulty is therefore distinguishing between mutations
that are driving cell survival and proliferation versus those which
merely are passengers, neutral changes that arose at precisely the
same time or as a consequence...
Posted February 26, 2008
Gene Directed Therapy: I told you so!! Roche Holding on the right track!
Analysis of: Study: More Complexity In Tailoring Cancer Drugs | online.wsj.com
Author: GLG Member Program Contributor
Analysis of: Study: More Complexity In Tailoring Cancer Drugs | online.wsj.com
Author: GLG Member Program Contributor
Roche Holding may well be leading the way to make gene analysis more cost effective and individualize cancer care by targeting the mutations!!
Posted February 26, 2008
Gardasil for boys: Not so tough sell!!!
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Member Program Contributor
Merck's HPV vaccine, Gardasil is expected to be approved for boys to extend "herd immunity" and offer more prevention to girls from cervical cancer. This " altruistic" goal comes with benefits for boys: eradication of 90 % of genital warts cases, and possible long term prevention of anal , penile, and...
Posted February 26, 2008
Accelerated approval for Avastin: Just the beginning
Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: GLG Member Program Contributor
Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: GLG Member Program Contributor
As expected, FDA gave accelerated approval for Genetech's Avastin in metastatic breast cancer, thus requiring Genentech to do further studies to show survival benefit and confirm the PFS survival. This decision will "officially" introduces Avastin to breast cancer market, where use has been already...
Posted February 25, 2008FDA Correctly Approves Avastin for Breast Cancer Based on PFS Advantage
Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: Eric Whitman, Medical Director, Office of Grants and Research Atlantic Health System Inc
FDA approval of Avastin in the treatment of advanced breast cancer will have an effect on the sales of the drug, but it is not clear to me how significant that effect will be, since it is already approved in Europe and has been widely used off-label for USA breast cancer patients already.
I am glad...
Posted February 25, 2008
Gardasil: Cervical Cancer Vaccine for Boys?? Can you say disingenuous?
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Member Program Contributor
Merck intends to market this viral vaccine to "protect" women from the risk of cervical carcinoma.
Posted February 25, 2008
Treanda Likely Big Winner in Indolent NHL
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Treanda Likely Big Winner in Indolent NHL
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Treanda (Bendamustine) combines the activity of a purine analog and alkylating agent, two of the most potent cytotoxic classes in therapy of indolent NHL. Older data from Europe as well as more recent clinical trials have confirmed the excellent activity of Treanda in indolent NHL and CLL. ...
Posted February 25, 2008
Avastin Approved in Breast Cancer: the correct thing was done
Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: GLG Member Program Contributor
Previous
Page :
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Next231 to
240
of 777Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: GLG Member Program Contributor
Avastin will be used in the therapy of "advanced" metastatic breast cancer, despite controversial data. In a disease with multiple options and a variable course it is virtually impossible to prove improved survival!!
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Painkiller Risk Found for Heart Patients
www.nytimes.com
FDA Asks if Pain Pill Is Tamper-Proof
online.wsj.com
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
www.pipelinereview.com
Hospitals See Drop in Paying Patients
www.nytimes.com
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
www.fiercebiotech.com
Will contact lens solutions cost more to ship and store?
November 13, 2008
Economy's impact on healthcare facilities
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
CVS Escalates the Generic Price War
November 13, 2008
A closer look
November 11, 2008

